Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The presence of blood in the urine is called hematuria. Kidney stones, urinary tract infections and hereditary diseases are some of the leading causes of hematuria. The urine does not contain red blood cells, and the presence of blood in urine can lead to a serious problem that can also cause kidney stones, urinary tract infections, and other hereditary diseases. The causes of blood in the urine are infections of the bladder, kidney or prostate, vigorous exercise, viral diseases such as hepatitis A virus, which causes liver disease and inflammation of the liver. More serious reasons that cause hematuria include bladder or kidney cancer, inflammation of the kidneys, urethra, bladder, or prostate. Increasing scope for the treatment is expected to offer significant growth opportunities to the hematuria treatment market in the forecast period.
The major factors driving the growth of the market is increasing geriatric population that is more susceptible to develop hematuria disease due to rising prevalence of urinary tract infection, kidney stone are some of the major reasons of hematuria among adults which is contributing to the growth of the market in the country. Also technological developments in medical devices and diagnostic procedures have led to various options for managing hematuria-associated indications such as kidney stones, bladder stones, and urinary tract infections are propelling the hematuria treatment market growth. The use of advanced treatment technologies and the continuous support from the U.S. government will offer lucrative growth opportunities in the country.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the United States hematuria treatment market. In addition, complete analysis of changes on the United States hematuria treatment market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 outbreak has substantially affected the incidence and management of kidney diseases including acute kidney injury (AKI), end-stage kidney disease, glomerulonephritis, and kidney transplantation. That positively contributes to the growth of the hematuria treatment market in the country.
The hematuria treatment market comprises of different market segment like type, indication, treatment and end user.
The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Macroscopic is visible blood in the urine where the urine appears pink, red, reddish-brown, or tea-colored. With microscopic hematuria, there is no visual evidence of the presence of blood unless the urine is examined under a microscope. In case of idiopathic hematuria there is no specific cause for the appearance of blood in the urine, and a family history of no kidney disease does not require specific treatment for idiopathic hematuria. The jogger’s hematuria most commonly occur in athletes due to hard training and rigorous exercise and the hematuria can range from serious to harmless in case of severity.
The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. Urinary tract infections are often caused by microorganisms, usually bacteria that invade the urethra and bladder and cause inflammation and infection. Urinary tract infections are most common in the urethra and bladder, but bacteria can travel up the ureters and infect the kidneys. Excessive level of calcium in the urine can cause kidney stones even people with a family history of kidney stones are more prone to kidney stones, which gradually lead to hematuria. In case if idiopathic hematuria which is commonly known as exercise hematuria which is a harmless condition that produces blood in the urine after strenuous exercise also it is more common in males than females.
The hematuria treatment market includes different treatments such as drugs, therapies. The healthcare professionals diagnose hematuria and its causes with a medical history, physical exam, urinalysis, and some additional tests. Adults diagnosed with microscopic hematuria with normal blood pressure and kidney function are recommended to undergo multiple urine tests over several months if still the presence of bold continues a kidney ultrasound may be performed. Treatment for hematuria depends on the following tests and the type of hematuria detected. In the absence of a family history of kidney disease, specific treatment to manage hematuria is not required. Hematuria in severe infection is due to kidney or bladder cancer, polycystic kidney disease, sickle cell anemia, or a family history of kidney disease that requires multiple tests to find the cause and advance treatment to cure hematuria. Even in some cases, antibiotic treatment is enough to treat the disease.
The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The treatment depends on the cause of the blood in your urine. To find out the cause, your doctor may ask about your family history and test your urine. A lab will test the urine sample for signs of an infection, kidney disease or other problems. Many patients with serious infection require dialysis multiple times a week in healthcare facilities. The incidence and management of kidney diseases, including acute kidney injury, end-stage kidney disease, glomerulonephritis, and kidney transplantation also due to the higher prevalence of comorbidities such as hypertension, diabetes, and chronic kidney disease that requires hospitalization has boosted the growth of the hospital segment.
The key players in hematuria treatment market are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH and The Medicines Company among others.
September 2021: AstraZeneca collaborated with VaxEquity for the discovery, development, and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
September 2021: Merck announced its definitive agreement to acquire Acceleron. Following the purchase of shares in the tender offer, Acceleron will become a subsidiary of Merck.
August 2021: Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for anticancer treatments.
June 2021: Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
July 2021: GlaxoSmithKline plc. and Alector, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
The report analyses the hematuria treatment market based on by type, indication, treatment, end user. The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. In microscopic hematuria there is no visual evidence of the presence of blood unless the urine is examined under a microscope. In case of idiopathic hematuria there is no specific cause for the appearance of blood in the urine, and a family history of no kidney disease does not require specific treatment. The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. Urinary tract infections are often caused by microorganisms, usually bacteria that invade the urethra and bladder and cause inflammation and infection. The hematuria treatment market includes different treatments such as drugs, therapies. The healthcare professionals diagnose hematuria and its causes with a medical history, physical exam, urinalysis, and some additional tests. Adults diagnosed with microscopic hematuria with normal blood pressure and kidney function are recommended to undergo multiple urine tests over several months if still the presence of bold continues a kidney ultrasound may be performed. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The treatment depends on the cause of the blood in your urine. To find out the cause, your doctor may ask about your family history and test your urine.
Why to buy this report
